Long-term amikacin liposome inhalation suspension in cystic fibrosis patients with chronic P. aeruginosa infection.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Bilton, Diana
  • Fajac, Isabelle
  • Pressler, Tacjana
  • Clancy, John Paul
  • Sands, Dorota
  • Minic, Predrag
  • Cipolli, Marco
  • Galeva, Ivanka
  • Quittner, Alexandra L.
  • Jumadilova, Zhanna
  • Ciesielska, Monika
  • Konstan, Michael W.
  • CLEAR-110 Study Group

Grupos

Abstract

. In CLEAR-108-a phase 3, randomised, open-label study-once-daily amikacin liposome inhalation suspension (ALIS) was noninferior to twice-daily tobramycin inhalation solution (TIS) in improving lung function in patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa infection after 3 treatment cycles (28 days on/28 days off). The CLEAR-110 extension study (ClinicalTrials.gov: NCT01316276; EudraCT: 2011-000443-24) assessed long-term safety, tolerability, and efficacy of ALIS in eligible patients who completed CLEAR-108.

Datos de la publicación

ISSN/ISSNe:
1569-1993, 1873-5010

Journal of Cystic Fibrosis  ELSEVIER

Tipo:
Article
Páginas:
1010-1017
PubMed:
34144923
Factor de Impacto:
1,818 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 19

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ALIS, Amikacin, Cystic fibrosis, Liposomal, Pseudomonas aeruginosa

Campos de Estudio

Cita

Compartir